Skip to main content
TipRanks
Go Ultimate75% OFF

Tanvex Biopharma (TANVF) Stock Statistics & Valuation Metrics

6 Followers

Total Valuation

Tanvex Biopharma has a market cap or net worth of $221.18M. The enterprise value is $12.13B.

Market Cap
$221.18M
Enterprise Value
$12.13B

Share Statistics

Tanvex Biopharma has 265,224,370 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
265,224,370
Owned by Insiders
―
Owned by Institutions
0.06%

Financial Efficiency

Tanvex Biopharma’s return on equity (ROE) is -0.26 and return on invested capital (ROIC) is -18.79%.

Return on Equity (ROE)
-0.26
Return on Assets (ROA)
-0.19
Return on Invested Capital (ROIC)
-18.79%
Return on Capital Employed (ROCE)
-0.19
Revenue Per Employee
1.86M
Profits Per Employee
-6.98M
Employee Count
215
Asset Turnover
0.05
Inventory Turnover
2.02

Valuation Ratios

The current PE Ratio of Tanvex Biopharma is -4.57. Tanvex Biopharma’s PEG ratio is -1.63.

PE Ratio
-4.57
PS Ratio
10.55
PB Ratio
1.47
Price to FCF
-4.17
Price to Operating Cash Flow
-7.80
PEG Ratio
-1.63

Income Statement

In the last 12 months, Tanvex Biopharma had revenue of 400.97M and earned -1.50B in profits. Earnings per share was -6.13.

Revenue
400.97M
Gross Profit
-440.71M
Operating Income
-1.39B
Pretax Income
-1.50B
Net Income
-1.50B
EBITDA
-1.02B
Earnings Per Share (EPS)
-6.13

Cash Flow

In the last 12 months, operating cash flow was -934.97M and capital expenditures -811.47M, giving a free cash flow of -1.75B billion.

Operating Cash Flow
-934.97M
Free Cash Flow
-1.75B
Free Cash Flow per Share
-6.59

Dividends & Yields

Tanvex Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-23.97%
Earnings Yield
-21.84%

Important Dates

Tanvex Biopharma upcoming earnings date is Mar 10, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 11, 2026
Next Earnings Date
Mar 10, 2027
Ex-Dividend Date
―

Financial Position

Tanvex Biopharma as a current ratio of 1.87, with Debt / Equity ratio of 27.72%

Current Ratio
1.87
Quick Ratio
1.35
Debt to Market Cap
0.00
Net Debt to EBITDA
-0.68
Interest Coverage Ratio
-29.39

Taxes

In the past 12 months, Tanvex Biopharma has paid -3.05M in taxes.

Income Tax
-3.05M
Effective Tax Rate
0.00

Enterprise Valuation

Tanvex Biopharma EV to EBITDA ratio is -7.27, with an EV/FCF ratio of -5.03.

EV to Sales
12.70
EV to EBITDA
-7.27
EV to Free Cash Flow
-5.03
EV to Operating Cash Flow
-9.39

Balance Sheet

Tanvex Biopharma has $592.56M in cash and marketable securities with $2.08B in debt, giving a net cash position of -$1.49B billion.

Cash & Marketable Securities
$592.56M
Total Debt
$2.08B
Net Cash
-$1.49B
Net Cash Per Share
-$5.62
Tangible Book Value Per Share
$5.88

Margins

Gross margin is -141.37%, with operating margin of -217.14%, and net profit margin of -230.36%.

Gross Margin
-141.37%
Operating Margin
-217.14%
Pretax Margin
-231.20%
Net Profit Margin
-230.36%
EBITDA Margin
-174.64%
EBIT Margin
-217.14%

Analyst Forecast

The average price target for Tanvex Biopharma is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
199.68%
EPS Growth Forecast
3.69%